Key facts
- This page summarizes Gary S. Jacob's Form 4 filing for Virpax Pharmaceuticals, Inc. (VRPX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2022, 16:18.
Gary S. Jacob - 01 Jan 2022 Form 4 Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)
- Reporting relationship
- Director
- Issuer ticker
- VRPX
- Reported as of
- 01 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 16:18:59 UTC
- Prior SEC filing
- 15 Jun 2021
- Next SEC filing
- 16 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Chipman, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gary S. Jacob filed Form 4 for Virpax Pharmaceuticals, Inc. (VRPX) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 15 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRPX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +12,091
- Change %
- Price
- $0.000000
- Shares after
- 12,091
- Date
- 01 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,091
- Exercise price
- $3.43
* marks a reported price that did not pass the local price check.